4:16PM Pharmasset reports 1Q10 results (VRUS) 22.68 +0.40 : Pharmasset reports 1Q10 earnings of ($0.49) vs ($0.43) First Call consensus; revs $0.3 mln vs $1.77 mln First Call consensus. "Pharmasset continues to make solid progress across all of its clinical programs." stated Schaefer Price, President and Chief Executive Officer. "2010 is shaping up to be an important year for the company with phase 2a data from our proprietary PSI-7977 program and phase 1 data with our first purine analog, PSI-938, coming in the third quarter. We believe nucleoside/tide analogs have the potential to become the backbone of treatment regimens, not only for genotype 1, but also across a broad range of HCV genotypes. We look forward to reporting data from all our programs throughout 2010."
surf's up......crikey
